New Oral Weight Loss Pill: Efficacy, Safety, and Comparison to Injectables

Introduction of the Oral GLP-1 Pill

• 💊 A new oral GLP-1 pill is emerging as an alternative to injectable weight loss drugs.
• 💡 Eli Lilly reports that this pill helped individuals lose an average of 12% of their body weight over 72 weeks.
• 🎯 This offers another option for patients, especially given the current shortages of injectable GLP-1 medications.

Efficacy Compared to Injectables

• 📉 The oral pill's effectiveness is less than that of injectable GLP-1s like Ozempic, Wegovy, Mounjaro, or Zepbound.
• ⚖️ Injectables can lead to weight loss of up to 27-30% over 12-18 months, whereas the oral version shows lower efficacy.
• 🔑 The oral pill may serve as a good maintenance option for those who have already achieved significant weight loss with injectables.

Importance of Body Composition and Fat Loss

• ⚠️ A crucial caveat is ensuring that weight loss primarily consists of body fat, not muscle or water.
• 📊 Patients should use body composition scales regularly (every 3-4 weeks) to monitor fat loss.
• 🎯 For women, achieving under 20% body fat and for men, under 15% body fat is recommended to prevent weight regain.

Safety and Peptide Concerns

• ❓ A significant concern is that this new drug is not a peptide, unlike Ozempic and others.
• 🧬 Peptides are amino acid strands naturally found in the body and are known for their safety and efficacy in various applications.
• ⚠️ The long-term safety profile of a non-peptide oral medication is uncertain, requiring further study and regulatory review.

Regulatory Status and Future Outlook

• 🗓️ The oral GLP-1 pill has not yet been submitted for regulatory review.
• 🚀 Submission is anticipated sometime this year, after which its future trajectory will become clearer.